 <h1>Clindamycin Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to clindamycin: oral capsule, oral powder for solution</i></p><p>Other dosage forms:</p><ul><li>solution</li></ul><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Powder for Solution)</p><p>Pseudomembranous colitis has been reported with nearly all antibacterial agents, including clindamycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. Because clindamycin therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate. Diarrhea, colitis, and pseudomembranous colitis have been observed to begin up to several weeks following cessation of therapy with clindamycin.</p><p class="blackboxWarning-title">Oral route (Capsule)</p><p>Clostridium difficile associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including clindamycin, and may range in severity from mild diarrhea to life-threatening colitis and has been observed to begin over 2 months after the administration of antibacterial agents. It is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents. If CDAD is confirmed or suspected, antibiotic therapy not directed against Clostridium difficile may need to be discontinued. Because clindamycin therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, clindamycin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking clindamycin:</p><p>
<i>Rare</i>
</p><ul>
<li>Cracks in the skin</li>
<li>loss of heat from the body</li>
<li>red, swollen skin scaly skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Abdominal or stomach cramps, pain, or tenderness</li>
<li>black, tarry stools</li>
<li>bleeding gums</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>bloating</li>
<li>blood in the urine or stools</li>
<li>blurred vision</li>
<li>chest pain</li>
<li>chills</li>
<li>clay-colored stools</li>
<li>cloudy urine</li>
<li>confusion</li>
<li>cough or hoarseness</li>
<li>dark urine</li>
<li>decrease in the amount of urine</li>
<li>diarrhea</li>
<li>diarrhea, watery and severe, which may also be bloody</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>dry mouth</li>
<li>fast heartbeat</li>
<li>fever with or without chills</li>
<li>general feeling of tiredness or weakness</li>
<li>headache</li>
<li>heartburn</li>
<li>heart stops</li>
<li>hives or welts, itching, or skin rash</li>
<li>increased thirst</li>
<li>itching of the vagina or genital area</li>
<li>joint or muscle pain</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>nausea or vomiting</li>
<li>no breathing</li>
<li>no pulse or blood pressure</li>
<li>pain during sexual intercourse</li>
<li>pain in the lower back or side</li>
<li>painful or difficult urination</li>
<li>pinpoint red spots on the skin</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>rash with flat lesions or small raised lesions on the skin</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>redness of the skin</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>swollen glands</li>
<li>thick, white vaginal discharge with no odor or with a mild odor</li>
<li>thirst</li>
<li>tightness in the chest</li>
<li>trouble breathing</li>
<li>unconscious</li>
<li>unpleasant breath odor</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight loss</li>
<li>vomiting of blood</li>
<li>yellow eyes or skin</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to clindamycin: compounding powder, injectable solution, intravenous solution, oral capsule, oral powder for reconstitution</i></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Pseudomembranous colitis, diarrhea, abdominal pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Dysgeusia, nausea, vomiting</p>
<p><b>Frequency not reported</b>: Esophageal ulcers, esophagitis (oral preparations)<sup>[Ref]</sup></p><p>The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment and is associated with the presence of Clostridium difficile toxin in the stool.  Pseudomembranous colitis may also be associated with toxic megacolon, which can be life-threatening.</p>
<p></p>
<p>An unpleasant or metallic taste has occasionally been reported after high doses of IV clindamycin.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Maculopapular rash</p>
<p><b>Uncommon</b> (0.1% to 1%): Urticaria</p>
<p><b>Rare</b> (less than 0.1%): Erythema multiforme, pruritus</p>
<p><b>Frequency not reported</b>: Toxic epidermal necrolysis, Stevens-Johnson syndrome, exfoliative dermatitis, bullous dermatitis, generalized mild to moderate morbilliform-like rash, acute generalized exanthematous pustulosis (AGEP), Sweet's Syndrome</p>
<p><b>Postmarketing reports</b>: Serious cutaneous adverse reaction<sup>[Ref]</sup></p><p>Rash was particularly common in AIDS patients.</p>
<p></p>
<p>A 47-year-old female patient with multiple comorbidities was diagnosed with Sweet's Syndrome.  The patient's symptoms developed 2 days after initiating oral clindamycin therapy for a tooth infection.  The patient's symptoms persisted despite tooth extraction and continuance of antibiotic treatment with intravenous, then oral, clindamycin.  Following discontinuation of clindamycin, the patient's symptoms resolved over several days.  Drug-induced Sweet's syndrome was determined based on the temporal relationship of the patient's symptoms, the beginning and end of clindamycin therapy, and the exclusion of other etiologies.</p>
<p></p>
<p>Three days after starting oral clindamycin for the persistence of symptoms following a root canal, a 34-year-old male patient reported "pimples" on his scalp which changed to pustules 24 hours later.  The lesions progressed and the patient's antibiotic therapy was discontinued.  Two days later, the rash improved considerably.  The patient met the diagnostic criteria for drug-induced Sweet's syndrome and clindamycin was the most likely cause due to the timeline of antibiotic therapy and the patient's improvement following its discontinuation.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Anaphylactoid reactions, drug reaction with eosinophilia and systemic systems (DRESS)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Thrombophlebitis (after IV infusion)</p>
<p><b>Uncommon</b> (0.1% to 1%): Cardiorespiratory arrest, hypotension<sup>[Ref]</sup></p><p>Cardiorespiratory arrest and hypotension have been reported after too rapid IV administration.  Thrombophlebitis has been reported after intravenous infusion.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Vaginitis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Eosinophilia</p>
<p><b>Frequency not reported</b>: Neutropenia, leucopenia, agranulocytosis, thrombocytopenia<sup>[Ref]</sup></p><p>Neutropenia (ANC 945 cells/mm3) occurred in a 68-year-old male 6 days after receiving a single 600 mg oral dose of clindamycin.  The neutrophil count normalized after 2 weeks.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Liver function test abnormalities</p>
<p><b>Frequency not reported</b>: Jaundice<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Injection site irritation, pain, abscess formation<sup>[Ref]</sup></p><p>Pain, induration, and sterile abscess have been reported after intramuscular administration.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Polyarthritis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Renal dysfunction, as shown by azotemia, oliguria, and/or proteinuria<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Milstone EB, McDonald AJ, Scholhamer CF Jr "Pseudomembranous colitis after topical application of clindamycin." Arch Dermatol 117 (1981): 154-5</p><p id="ref_2">2. Davies J, Beck E "Recurrent colitis following antibiotic-associated pseudomembranous colitis." Postgrad Med J 57 (1981): 599-601</p><p id="ref_3">3. Bartlett JG "Narrative review: the new epidemic of Clostridium difficile-associated enteric disease." Ann Intern Med 145 (2006): 758-64</p><p id="ref_4">4. Leigh DA, Simmons K, Williams S "Gastrointestinal side effects following clindamycin and lincomycin treatment: a follow up study." J Antimicrob Chemother 6 (1980): 639-45</p><p id="ref_5">5. George WL,  Sutter VL,  Finegold SM "Antimicrobial agent-induced diarrhea--a bacterial disease." J Infect Dis 136 (1977): 822-8</p><p id="ref_6">6. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_7">7. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_8">8. "Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn, Kalamazoo, MI. </p><p id="ref_9">9. de Groot MC,  van Puijenbroek EP "Clindamycin and taste disorders." Br J Clin Pharmacol 64 (2007): 542-5</p><p id="ref_10">10. Meadowcroft AM, Diaz PR, Latham GS "Clostridium difficile toxin-induced colitis after use of clindmycin phosphate vaginal cream." Ann Pharmacother 32 (1998): 309-11</p><p id="ref_11">11. Cone JB, Wetzel W "Toxic megacolon secondary to pseudomembranous colitis." Dis Colon Rectum 25 (1982): 478-82</p><p id="ref_12">12. Wilson DH "Clindamycin in the treatment of soft tissue infections: a review of 15,019 patients." Br J Surg 67 (1980): 93-6</p><p id="ref_13">13. Mason SJ, O'Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981): 115-20</p><p id="ref_14">14. Geddes AM,  Bridgwater FA,  Williams DN,  Oon J,  Grimshaw GJ "Clinical and bacteriological studies with clindamycin." Br Med J 2 (1970): 703-4</p><p id="ref_15">15. Van Ness MM, Cattau EL Jr "Fulminant colitis complicating antibiotic-associated pseudomembranous colitis: case report and review of the clinical manifestations and treatment." Am J Gastroenterol 82 (1987): 374-7</p><p id="ref_16">16. Parry MF, Rha CK "Pseudomembranous colitis caused by topical clindamycin phosphate." Arch Dermatol 122 (1986): 583-4</p><p id="ref_17">17. Clark BM,  Homeyer DC,  Glass KR,  D'Avignon LC "Clindamycin-Induced Sweet's Syndrome." Pharmacotherapy 27 (2007): 1343-6</p><p id="ref_18">18. Vidal C, Iglesias A, Saez A, Rodriguez M "Hypersensitivity to clindamycin." DICP 25 (1991): 317</p><p id="ref_19">19. Kapoor R,  Flynn C,  Heald PW,  Kapoor JR "Acute generalized exanthematous pustulosis induced by clindamycin." Arch Dermatol 142 (2006): 1080-1</p><p id="ref_20">20. Tian D,  Mohan RJ,  Stallings G "Drug rash with eosinophilia and systemic symptoms syndrome associated with clindamycin." Am J Med 123 (2010): e7-8</p><p id="ref_21">21. Miller Quidley A,  Bookstaver PB,  Gainey AB,  Gainey MD "Fatal clindamycin-induced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome." Pharmacotherapy  (2012):</p><p id="ref_22">22. Paquet P, Schaaflafontaine N, Pierard GE "Toxic epidermal necrolysis following clindamycin treatment." Br J Dermatol 132 (1995): 665-6</p><p id="ref_23">23. Lammintausta K,  Tokola R,  Kalimo K "Cutaneous adverse reactions to clindamycin: results of skin tests and oral exposure." Br J Dermatol 146 (2002): 643-8</p><p id="ref_24">24. Bubalo JS,  Blasdel CS,  Bearden DT "Neutropenia after single-dose clindamycin for dental prophylaxis." Pharmacotherapy 23 (2003): 101-3</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What are the best antibiotics for a tooth infection?</li>
<li>What is the best antibiotic to treat strep throat?</li>
<li>Can clindamycin be used to treat chlamydia?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about clindamycin</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>702 Reviews</li>
<li>Drug class: lincomycin derivatives</li>
<li>FDA Alerts (1)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Clindamycin &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Clindamycin Oral, Injection, Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Cleocin, Cleocin Pediatric, Cleocin HCl, Cleocin Phosphate</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +6 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Bacterial Endocarditis Prevention</li>
<li>Aspiration Pneumonia</li>
<li>Bacteremia</li>
<li>Babesiosis</li>
<li data-more-config-id="list-data-resources-conditions">... +19 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to clindamycin: compounding powder, injectable solution, intravenous solution, oral capsule, oral powder for reconstitution</i></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Pseudomembranous colitis, diarrhea, abdominal pain</p><p><b>Uncommon</b> (0.1% to 1%): Dysgeusia, nausea, vomiting</p><p><b>Frequency not reported</b>: Esophageal ulcers, esophagitis (oral preparations)<sup>[Ref]</sup></p><p>The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment and is associated with the presence of Clostridium difficile toxin in the stool.  Pseudomembranous colitis may also be associated with toxic megacolon, which can be life-threatening.</p><p></p><p>An unpleasant or metallic taste has occasionally been reported after high doses of IV clindamycin.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Maculopapular rash</p><p><b>Uncommon</b> (0.1% to 1%): Urticaria</p><p><b>Rare</b> (less than 0.1%): Erythema multiforme, pruritus</p><p><b>Frequency not reported</b>: Toxic epidermal necrolysis, Stevens-Johnson syndrome, exfoliative dermatitis, bullous dermatitis, generalized mild to moderate morbilliform-like rash, acute generalized exanthematous pustulosis (AGEP), Sweet's Syndrome</p><p><b>Postmarketing reports</b>: Serious cutaneous adverse reaction<sup>[Ref]</sup></p><p>Rash was particularly common in AIDS patients.</p><p></p><p>A 47-year-old female patient with multiple comorbidities was diagnosed with Sweet's Syndrome.  The patient's symptoms developed 2 days after initiating oral clindamycin therapy for a tooth infection.  The patient's symptoms persisted despite tooth extraction and continuance of antibiotic treatment with intravenous, then oral, clindamycin.  Following discontinuation of clindamycin, the patient's symptoms resolved over several days.  Drug-induced Sweet's syndrome was determined based on the temporal relationship of the patient's symptoms, the beginning and end of clindamycin therapy, and the exclusion of other etiologies.</p><p></p><p>Three days after starting oral clindamycin for the persistence of symptoms following a root canal, a 34-year-old male patient reported "pimples" on his scalp which changed to pustules 24 hours later.  The lesions progressed and the patient's antibiotic therapy was discontinued.  Two days later, the rash improved considerably.  The patient met the diagnostic criteria for drug-induced Sweet's syndrome and clindamycin was the most likely cause due to the timeline of antibiotic therapy and the patient's improvement following its discontinuation.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Anaphylactoid reactions, drug reaction with eosinophilia and systemic systems (DRESS)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Thrombophlebitis (after IV infusion)</p><p><b>Uncommon</b> (0.1% to 1%): Cardiorespiratory arrest, hypotension<sup>[Ref]</sup></p><p>Cardiorespiratory arrest and hypotension have been reported after too rapid IV administration.  Thrombophlebitis has been reported after intravenous infusion.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Vaginitis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Eosinophilia</p><p><b>Frequency not reported</b>: Neutropenia, leucopenia, agranulocytosis, thrombocytopenia<sup>[Ref]</sup></p><p>Neutropenia (ANC 945 cells/mm3) occurred in a 68-year-old male 6 days after receiving a single 600 mg oral dose of clindamycin.  The neutrophil count normalized after 2 weeks.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Liver function test abnormalities</p><p><b>Frequency not reported</b>: Jaundice<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Injection site irritation, pain, abscess formation<sup>[Ref]</sup></p><p>Pain, induration, and sterile abscess have been reported after intramuscular administration.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Polyarthritis<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Renal dysfunction, as shown by azotemia, oliguria, and/or proteinuria<sup>[Ref]</sup></p><p id="ref_1">1. Milstone EB, McDonald AJ, Scholhamer CF Jr "Pseudomembranous colitis after topical application of clindamycin." Arch Dermatol 117 (1981): 154-5</p><p id="ref_2">2. Davies J, Beck E "Recurrent colitis following antibiotic-associated pseudomembranous colitis." Postgrad Med J 57 (1981): 599-601</p><p id="ref_3">3. Bartlett JG "Narrative review: the new epidemic of Clostridium difficile-associated enteric disease." Ann Intern Med 145 (2006): 758-64</p><p id="ref_4">4. Leigh DA, Simmons K, Williams S "Gastrointestinal side effects following clindamycin and lincomycin treatment: a follow up study." J Antimicrob Chemother 6 (1980): 639-45</p><p id="ref_5">5. George WL,  Sutter VL,  Finegold SM "Antimicrobial agent-induced diarrhea--a bacterial disease." J Infect Dis 136 (1977): 822-8</p><p id="ref_6">6. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_7">7. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_8">8. "Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn, Kalamazoo, MI. </p><p id="ref_9">9. de Groot MC,  van Puijenbroek EP "Clindamycin and taste disorders." Br J Clin Pharmacol 64 (2007): 542-5</p><p id="ref_10">10. Meadowcroft AM, Diaz PR, Latham GS "Clostridium difficile toxin-induced colitis after use of clindmycin phosphate vaginal cream." Ann Pharmacother 32 (1998): 309-11</p><p id="ref_11">11. Cone JB, Wetzel W "Toxic megacolon secondary to pseudomembranous colitis." Dis Colon Rectum 25 (1982): 478-82</p><p id="ref_12">12. Wilson DH "Clindamycin in the treatment of soft tissue infections: a review of 15,019 patients." Br J Surg 67 (1980): 93-6</p><p id="ref_13">13. Mason SJ, O'Meara TF "Drug-induced esophagitis." J Clin Gastroenterol 3 (1981): 115-20</p><p id="ref_14">14. Geddes AM,  Bridgwater FA,  Williams DN,  Oon J,  Grimshaw GJ "Clinical and bacteriological studies with clindamycin." Br Med J 2 (1970): 703-4</p><p id="ref_15">15. Van Ness MM, Cattau EL Jr "Fulminant colitis complicating antibiotic-associated pseudomembranous colitis: case report and review of the clinical manifestations and treatment." Am J Gastroenterol 82 (1987): 374-7</p><p id="ref_16">16. Parry MF, Rha CK "Pseudomembranous colitis caused by topical clindamycin phosphate." Arch Dermatol 122 (1986): 583-4</p><p id="ref_17">17. Clark BM,  Homeyer DC,  Glass KR,  D'Avignon LC "Clindamycin-Induced Sweet's Syndrome." Pharmacotherapy 27 (2007): 1343-6</p><p id="ref_18">18. Vidal C, Iglesias A, Saez A, Rodriguez M "Hypersensitivity to clindamycin." DICP 25 (1991): 317</p><p id="ref_19">19. Kapoor R,  Flynn C,  Heald PW,  Kapoor JR "Acute generalized exanthematous pustulosis induced by clindamycin." Arch Dermatol 142 (2006): 1080-1</p><p id="ref_20">20. Tian D,  Mohan RJ,  Stallings G "Drug rash with eosinophilia and systemic symptoms syndrome associated with clindamycin." Am J Med 123 (2010): e7-8</p><p id="ref_21">21. Miller Quidley A,  Bookstaver PB,  Gainey AB,  Gainey MD "Fatal clindamycin-induced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome." Pharmacotherapy  (2012):</p><p id="ref_22">22. Paquet P, Schaaflafontaine N, Pierard GE "Toxic epidermal necrolysis following clindamycin treatment." Br J Dermatol 132 (1995): 665-6</p><p id="ref_23">23. Lammintausta K,  Tokola R,  Kalimo K "Cutaneous adverse reactions to clindamycin: results of skin tests and oral exposure." Br J Dermatol 146 (2002): 643-8</p><p id="ref_24">24. Bubalo JS,  Blasdel CS,  Bearden DT "Neutropenia after single-dose clindamycin for dental prophylaxis." Pharmacotherapy 23 (2003): 101-3</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What are the best antibiotics for a tooth infection?</li>
<li>What is the best antibiotic to treat strep throat?</li>
<li>Can clindamycin be used to treat chlamydia?</li>
</ul><h2>More about clindamycin</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Support Group</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>702 Reviews</li>
<li>Drug class: lincomycin derivatives</li>
<li>FDA Alerts (1)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Clindamycin &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
<li>Clindamycin Oral, Injection, Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +6 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Bacterial Endocarditis Prevention</li>
<li>Aspiration Pneumonia</li>
<li>Bacteremia</li>
<li>Babesiosis</li>
<li data-more-config-id="list-data-resources-conditions">... +19 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>